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Abstract Anorexia nervosa (AN) and bulimia nervosa
(BN) are complex disorders characterized by disordered
eating behavior where the patient’s attitude towards weight
and shape, as well as their perception of body shape, are
disturbed. Formal genetic studies on twins and families
suggested a substantial genetic influence for AN and BN.
Candidate gene studies have initially focused on the sero-
tonergic and other central neurotransmitter systems and on
genes involved in body weight regulation. Hardly any of
the positive findings achieved in these studies were
unequivocally confirmed or substantiated in meta-analyses.
This might be due to too small sample sizes and thus low
power and/or the genes underlying eating disorders have
not yet been analyzed. However, some studies that also
used subphenotypes (e.g., restricting type of AN) led to
more specific results; however, confirmation is as yet
mostly lacking. Systematic genome-wide linkage scans
based on families with at least two individuals with an
eating disorder (AN or BN) revealed initial linkage regions
on chromosomes 1, 3 and 4 (AN) and 10p (BN). Analyses
on candidate genes in the chromosome 1 linkage region led
to the (as yet unconfirmed) identification of certain variants
associated with AN. Genome-wide association studies are
under way and will presumably help to identify genes and
pathways involved in these eating disorders. The elucida-
tion of the molecular mechanisms underlying eating dis-
orders might improve therapeutic approaches.
Keywords 5-HT2A receptor gene 
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Introduction
Anorexia nervosa (AN) and bulimia nervosa (BN) are
complex eating disorders that are commonly defined by
criteria either of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR) [1] or the International
Statistical Classification of Diseases and Related Health
Problems (ICD-10) [2]. Formal genetic studies suggest a
substantial genetic influence in these disorders [3–6]. Dis-
turbances of neurotransmitter, neuropeptide, and neuroen-
docrine systems have been reported in acutely ill and
patients who have been followed up for several years [7] so
that an involvement of these systems in the etiology of eating
disorders appears possible. As candidate gene approaches
did not unequivocally identify susceptibility genes (alleles)
for AN or BN, systematic model-free genome-wide linkage
screens have been performed in order to identify unknown
genes involved in the etiology of these eating disorders.
Twin and family studies
Twin studies can be powerful, but their methodology is
complicated and their results are easily misjudged. Caveats
regarding twin studies include ascertainment and power
issues [8]. Use of a clinical sample for a twin study usually
implies a greater severity of the illness; hence, the genetic
loading might be different from that of patients from the
general population. Additionally, factors like an equal
environment assumption, as well as the generalizability of
results need to be considered [9].
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Evidence from family and twin studies suggests a sub-
stantial genetic contribution to the etiology of both AN and
BN [4, 10–15]. Holland et al. [10] showed proband-wise
concordance rates for AN of 0.71 for monozygotic twins
and 0.1 for dizygotic twins. Heritability estimates based on
these rates ranged from 0.86 to 0.98 for AN [11]. Higher
concordance rates for monozygotic twins than for dizygotic
twins have been shown in most twin studies. However,
Walters and Kendler [16] could not detect a genetic com-
ponent to AN. They analyzed an epidemiological female
twin sample (n = 2,163); only a small number of twins
were retrospectively diagnosed with AN. Surprisingly,
concordance rates were higher for dizygotic than for
monozygotic twins. Interestingly, co-twins of index cases
with AN had significantly lower body mass index (BMI in
kg/m2) and higher depression rates than co-twins of unaf-
fected twins. Overlapping of the genetic predisposition to
both BN and depression was found in the Virginia twin
study [16]. Interestingly, Klump et al. [17] found that
genetic effects were significantly more important for dis-
ordered eating during mid to late adolescence than during
prepubertal adolescence. Puberty may therefore be a criti-
cal period to activate some of the genetic factors which
make certain individuals more susceptible for the devel-
opment of eating disorders. Klump et al. [15] identified 26
AN patients by interviewing 672 female 17-year-old twins.
Biometrical analyses indicated that genetic and non-shared
environmental factors accounted for 74 and 26% of the
variance in AN, respectively. Based on data of the Swedish
Twin Registry, Bulik et al. [18] estimate the heritability of
AN at 56%, with the remaining variance attributable to
shared environment (5%) and non-shared environment
(39%).
Two controlled family studies have found an average
3% lifetime risk of AN in first-degree relatives of
patients, being equivalent to an approximate relative risk
of at least 10 [7, 19, 20]. AN was found to be infrequent
in 1,831 relatives of 504 patients with eating disorders,
whereas full and partial syndromes of these eating dis-
orders aggregated in female relatives of both anorexic and
bulimic probands (Strober et al. [21]). Relative risks were
11.3 and 12.3 for the full syndrome of AN in first-degree
female relatives of patients with AN or BN, respectively
[21], suggesting that specific genes can predispose to both
eating disorders. The relative risks for BN were 4.2 and
4.4 for first-degree female relatives of patients with AN or
BN, respectively. Overlapping of the genetic predisposi-
tion to both BN and depression was found in the Virginia
twin study [22]. Interestingly, Klump et al. [17] found
that genetic effects were significantly more important for
disordered eating during mid to late adolescence than
during prepubertal adolescence, accounting for 46% of
variance from 14 to 18 years of age versus only 6% of
variance at 11 years of age. Puberty may therefore be a
critical period to activate some of the genetic factors
which make certain individuals more susceptible to the
development of eating disorders.
Candidate gene studies
Basically, two approaches are involved in the molecular
genetic analysis of a complex phenotype: (1) association
studies (case–control studies; Table 1), including genome-
wide association studies (GWAS) and (2) family-based
linkage studies. Both approaches have in general been used
for molecular genetic studies of eating disorders, although
GWAS are still lacking. The candidate gene approach
relies on genetic, physiological, biochemical or pharma-
cological evidence to determine the involvement of a
specific gene in the analyzed phenotype.
Candidate gene studies in eating disorders need to
consider the following clinical observations: (a) the prev-
alence of AN and BN is considerably higher in females
(ratio 9:1). (b) The manifestation periods for both AN and
BN are predominantly in puberty and late adolescence,
respectively. (c) Approximately 30% of patients with AN
later on develop BN; the opposite sequence is less frequent.
(d) There is a high rate of comorbidity with obsessive
compulsive disorder, major depression and generalized
anxiety disorder [7, 23, 24].
In general terms, the lower the numbers of regulatory
pathways involved in a complex phenotype, the fewer
genes are likely to be involved. An example of such a
putative narrow pathway into AN is weight loss-induced
dysregulation of the maintenance of a normal body weight,
for whatever reason, during the critical age period. If,
however, subtle perturbations in several different pathways
lead to an eating disorder, greater the heterogeneity and
smaller the effect of a predisposing allele is likely to be.
Molecular genetic analyses of other complex disorders
suggest that the genetic basis underlying eating disorders is
polygenic; effect sizes of predisposing alleles are likely to
be small [Hebebrand et al., this issue].
Neurobiological disturbances that persist after recovery
might be trait-related and thus implicated in the etiology of
the disorder. Studies pertaining to long-term follow-up of
patients with AN suggest that disturbances of monoamin-
ergic pathways and weight regulation continue after
recovery [25–28]. These studies implicate that genes
involved in the serotonergic and dopaminergic systems and
in weight regulation can be perceived as candidates [29].
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Table 1 Summary of candidate genes selected from association studies for AN and BN
Gene Variant Test type Evidence for association
to
Study
AN BN
Catechol-O-methyltransferase
(COMT)
Val-158-Met TDT Yes ND Frisch et al. [66]
Val-158-Met TDT Yes ND Michaelovsky et al. [68]
Val-158-Met CC Yes Yes Frieling et al. [150]
Val-158-Met CC Yes No Mikolajczyk et al. [69]
Val-158-Met TDT No ND Gabrovsek et al. [70]
Dopamine D2 receptor (DRD2) TaqA1 CC Yes Yes Nisoli et al. [65]
-141 Indel TDT/CC Yes ND Bergen et al. [64]
Dopamine D3 receptor (DRD3) Bal I polymorphism in exon 1 CC No ND Bruins-Slot et al. [151]
Dopamine D4 receptor (DRD4) 13 bp deletion
48 bp deletion
TDT No ND Hinney et al. [60]
Haplotype exon III VNTR, 120 bp
repeat, 521C[T, 809A[G
TDT Yes ND Bachner-Melman et al. [59]
Exon III VNTR CC Yes Kaplan et al. [63]
Exon III VNTR CC No Karwautz et al. [61]
Serotonin transporter (SERT, 5-
HTT, SCL6A4)
5-HTTLPR CC No ND Sundaramurthy et al. [50]
5-HTTLPR CC Yes ND Matsushita et al. [49]
5-HTTLPR intron 2 VNTR CC ND No Lauzurica et al. [51]
5-HTTLPR Meta-analysis Yes ND Gorwood et al. [52]
5-HTTLPR TDT No ND Urwin et al. [55]
5-HTTLPR CC No ND Rybakowski et al. [40]
5-HTTLPR CC No Yes Di Bella et al. [152]
5-HTTLPR CC Yes ND Fumeron et al. [153]
5-HTTLPR CC No ND Hinney et al. [48]
5-HT1B/1Db receptor 821G[C CC Yes ND Levitan et al. [154]
Phe-124-Cys CC No ND Hinney et al. [155]
5-HT2A receptor -1438 G/A CC Yes ND Rybakowski et al. [40]
-1438 G/A CC No ND Ando et al. [42]
-1438 G/A CC No Yes Nishiguchi et al. [46]
-1438 G/A TDT No ND Gorwood et al. [45]
-1438 G/A Meta-analysis Yes ND Gorwood et al. [52]
-1438 G/A CC Yes No Nacmias et al. [39]
-1438 G/A CC Yes ND Collier et al. [37]
-1438 G/A CC No ND Hinney et al. [156]
-1438 G/A CC No ND Campbell et al. [44]
-1438 G/A CC Yes ND Sorbi et al. [41]
5-HT2A receptor -1438 G/A CC Yes No Enoch et al. [38]
-1438 G/A CC No No Ziegler et al. [47]
-1438 G/A CC Yes Yes Ricca et al. [157]
-1438 G/A CC No ND Kipman et al. [96]
Thr-25-Asn 102T[C, 516C[T,
His-452-Tyr
CC No ND Hinney et al. [48]
Thr-25-Asn 102T[C, His-452-Tyr CC No No Nacmias et al. [39]
5-HTR3B receptor Tyr129Ser CC Yes No Hammer et al. [158]
Norepinephrine transporter gene
(NET, SLC6A2)
4-bp ins/del in AAGG4 repeat
island
TDT Yes ND Urwin et al. [53]
Epistasis between 4-bp ins/del in
AAGG4 repeat island and
5-HTTLPR
TDT No ND Urwin et al. [55]
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Neurotransmitter systems implicated in eating
disorders
Serotonergic system
Serotonin (5-hydroxytryptamine; 5-HT) is involved in a
broad range of biological, physiological and behavioral
functions [30, 31]. The neurotransmitter system includes
tryptophan hydroxylase, the 5-HT transporter (SLC6A4 or
5-HTT) and 5-HT receptors. Several lines of evidence
implicate the serotonergic system in body weight regula-
tion and more specifically in eating behavior [30–32] and
eating disorders [33, 34]. In cerebrospinal fluid 5-hydrox-
yindoleacetic acid (5-HIAA) levels were elevated in
long-term weight-restored patients with AN or BN in
comparison with controls, suggesting that hyperserotoner-
gic function is a trait marker in eating disorders [35]. The
increased serotonergic neurotransmission could also
account for characteristic psychopathological features such
as perfectionism, rigidity and obsessiveness frequently
associated with AN [7, 23]. However, results of most of the
molecular genetic studies pertaining to the serotonergic
system were negative or equivocal see [36]. Two excep-
tions should be mentioned:
1. The A-allele of the promoter polymorphism -
1438G[A of the 5-HT2A receptor gene was initially
reported to be associated with AN [37]. Some of the
subsequent studies confirmed this result [38–41],
others did not [42–46]. Additionally, an early meta-
Table 1 continued
Gene Variant Test type Evidence for association
to
Study
AN BN
Leptin -1387G[A (promoter) CC No No Hinney et al. [81]
Agouti related protein 526G[A (silent) in linkage
disequilibrium with Ala-67-Thr
605C[T (silent)
CC
CC
Yes
No
ND Vink et al. [83]
Pro-opiomelanocortin (POMC) Insertion of 9 bp between codon
73 and 74
CC No ND Hinney et al. [159]
Brain-derived neurotrophic factor
(BDNF)
-270C[T,
Val-66-Met
CC Yes ND Ribase´s et al. [105]
-270C[T,
Val-66-Met
CC Yes Yes Ribase´s et al. [106]
-270C[T,
Val-66-Met
FBAT Yes ND Ribase´s et al. [114]
-270C[T,
Val-66-Met
CC No No Friedel et al. [108]
-270C[T,
Val-66-Met
CC Yes ND Rybakowski et al. [109]
Val-66-Met TDT No ND Dardennes et al. [23]
-270C[T,
Val-66-Met
nd Yes Kaplan et al. [84]
Neurotrophic tyrosine kinase
receptor type 3 (NTRK3)
rs7180942 FBAT Yes Yes Mercader et al. [110]
Cannabinoid receptor gene
(CNR1)
rs1049353 rs2180619 rs806379
rs1535255 rs2023239
TDT/CC No ND Mu¨ller et al. [113]
AAT trinucleotide repeat ETDT Yes ND Siegfried et al. [43]
Fatty acid amide hydrolase
(FAAH)
rs932816
rs324420 rs324419
rs873978 rs2295632
TDT No ND Mu¨ller et al. [113]
N-acylethanolamine-hydrolyzing
acid amidase (NAAA)
rs2292534 rs4859567 rs10518142
rs6819442
TDT No ND Mu¨ller et al. [113]
Monoglyceride lipase (MGLL) rs893294 TDT No ND Mu¨ller et al. [113]
TDT Transmission disequilibrium test, CC case–control study, ND no data
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analysis showed lack of association [47]. A later meta-
analysis, comprising more studies, showed that a large
heterogeneity between samples exists, but the associ-
ation of the -1438A allele persisted for AN [6].
Hence, the 5-HT2A receptor gene might tentatively be
considered as a candidate gene for AN.
2. The promoter region of the serotonin transporter (5-
HTTLPR) harbors a functional insertion/deletion poly-
morphism with two frequent alleles that were desig-
nated as short (*S) and long (*L) alleles. The
frequency of the 5-HTTLPR *S allele has been
assessed in AN [48–50] and BN [51], with conflicting
results. A meta-analysis for AN indicates that the *S
allele could represent a risk factor for AN [52].
Norepinephrine
In long-term weight-restored patients with AN, lower
serum norepinephrine levels than in controls were mea-
sured [53]. A repeat polymorphism within the norepi-
nephrine transporter (SLC6A2 or NET) promoter region
alters a potential transcription factor binding site therefore
presumably entailing altered norepinephrine reuptake.
Preferential transmission of the L4 allele was detected in
87 Australian trios each comprising a patient with AN of
the restricting type and both biological parents. These
results suggested that L4 or a DNA variant in linkage
disequilibrium with it doubles the risk to develop this type
of AN [53]. Following up on previous studies [48, 53, 54]
on single genes, Urwin et al. [55] investigated epistasis
between the 5-HTT and NET in AN. However, epistasis
between the 5-HTTLPR and the polymorphism within the
NET promoter polymorphic region (NETpPR) was not
observed.
Dopaminergic system
The dopaminergic system has been implicated in the
pathophysiology of AN and BN [23, 56, 57]. For example,
major symptoms related to AN like repulsion to food,
weight loss, hyperactivity, distortion of body image, and
obsessive–compulsive behavior have all been related to
dopamine activity [58].
Association studies on the role of polymorphisms in the
dopamine D4 receptor gene (DRD4), mainly the 7-repeat
allele of the DRD4 exon 3 repeat, in AN have yielded
positive [59] as well as negative results [60, 61]. The 7-
repeat allele is seemingly relevant for binge eating disorder
(BED) and BN: Levitan et al. [62] identified an elevated
rate of binge eaters in a group of carriers of the 7-repeat
allele. A similar finding was reported by Kaplan et al. [63]
who showed that the 7-repeat allele of DRD4 contributes to
weight gain in woman with BN. Bergen et al. [64] analyzed
seven polymorphisms within the dopamine D2 receptor
gene (DRD2) and reported nominal association for two of
them and AN. However, Nisoli et al. [65] did confirm the
association with AN or BN.
The catechol-O-methyltransferase gene (COMT) catab-
olizes brain catecholamine neurotransmitters such as
dopamine and norepinephrine. An initial study suggested
an influence of the Val158Met polymorphism on suscep-
tibility to AN [66]. Data were confirmed in some [67–69]
but not all studies [64, 70].
As most of the reported studies on the genetic influence
of the dopaminergic system on the etiology of AN and BN
did not have sufficient statistical power, these findings
require replication in large independent samples or at least
in a meta-analytical approach.
Body weight regulation: leptinergic–melanocortinergic
system
There has been a tremendous increase in the number of
molecular genetic studies pertaining to body weight regu-
lation in the last 15 years see also [Hinney et al.]. Since its
discovery in 1994, research has focused on leptin-mediated
signaling pathways. Leptin is not only a key hormone
implicated in the regulation of energy balance, but it is also
a pleiotropic hormone involved in various neuroendocrine
and behavioral alterations associated with profound chan-
ges in energy storage, including the adaptation of the
organism to semi-starvation [71, 72].
Hypoleptinemia is a cardinal feature of acute AN, and in
most studies the low leptin levels are typically below those
of healthy gender- and age-matched controls and reflect the
low fat mass, thus signaling energy depletion to the brain. In
most studies, circulating levels of leptin were highly cor-
related with percent body fat [50, 73–78] and, to a lesser
extent, with BMI on referral [26, 39, 50, 73, 76, 78]. In
further studies patients who had recovered from eating
disorders also had reduced serum leptin levels after
adjustment for BMI and/or fat mass [79], suggesting that
relative hypoleptinemia might be a trait marker in eating
disorders. According to Frey et al. [25] females with a past
history of AN (followed up 10-years after in-patient treat-
ment) seemingly have a lower percent body fat and a trend
to lower serum leptin levels than BMI-matched controls.
However, other studies did not confirm such findings [80].
A mutation analysis of the coding region and part of the
promoter region of the leptin gene in patients with AN,
followed by case–control studies of the detected poly-
morphisms, yielded negative results [81]. Leptin receptor
gene SNPs also do not appear to be associated with regu-
lation of body weight or with AN [82].
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Agouti related peptide (AGRP) is an important orexi-
genic peptide that regulates energy balance downstream of
leptin. AGRP is an endogenous inverse agonist at mela-
nocortinergic receptors and therefore involved in body
weight regulation. Loss-of-function mutations in AGRP
could result in an inadequate starvation signaling in the
brain. In patients with AN three polymorphisms were
detected in AGRP. The Ala67 allele was significantly
enriched in patients with AN compared to controls [83]. In
contrast, another study [84] observed over-transmission of
the other allele (67Thr) to patients with AN (114 AN-trios).
Hence, an influence of variations within AGRP on the
development of AN is currently not shown unequivocally.
Melanocortin-4 receptor
A dominant form of obesity is conferred by mutations in
MC4R that lead to a reduced receptor function e.g., [85–
91]. Obesity has been identified as a risk factor for the
development of BN [92]. Accordingly, genotypes predis-
posing to obesity might be detected more commonly in
patients with BN than in controls not selected for body
weight. A mutation screen in the MC4R of 81 BN patients
revealed that a single extremely obese patient had a haplo-
insufficiency mutation in the MC4R. This was the first
report on the detection of a validated genotype predispos-
ing to obesity in a patient with BN [93]. Two further
studies described that all identified obese carriers of MC4R
variants were shown to have BED [94–96]. However,
Branson et al. [94] included the Ile103 variant of the
Val103Ile polymorphism as one of the risk alleles; this
allele was however subsequently found to be negatively
associated with obesity [95–97]. Furthermore, another
study did not detect any MC4R mutation among extremely
obese adults with BED [98]. Finally, in our own families
with a total of 43 MC4R mutation carriers we found no
evidence for elevated rates of binge eating behavior in
carriers of MC4R mutations [99]. In conclusion, it is
unlikely that BED is strongly associated with MC4R
mutations.
Brain-derived neurotrophic factor (BDNF)
BDNF acts downstream of the MC4R [100]. It regulates
synaptic efficiency through the modulation of key neuro-
transmitter systems previously shown to be involved in ED.
BDNF is expressed in the hypothalamic nuclei associated
with weight regulation and feeding control. Bdnf?/- mice
show altered eating behavior, increased body weight and
hypertrophic adipocytes. Humans with low serum BDNF
levels display an aberrant eating behavior [101, 102].
BDNF levels might be involved in the severity of eating
disorders (EDs) through the modulation of
psychopathological traits that are associated with the ED
phenotype [103]. Very recently, Ehrlich et al. [104] mea-
sured in acute patients with AN, in addition to hypolep-
tinemia, reduced peripheral BDNF concentrations. Short-
term recovered patients had elevated BDNF levels com-
pared with acutely underweight patients. This might be part
of a regenerative process after biochemical and molecular
neuronal injury and may also be related to the regulation of
appetite and eating behavior [104]. Several studies inves-
tigated the role of the BDNF non-synonymous polymor-
phism Val66Met in the etiology of EDs. The 66Met variant
was found to be associated with AN restricting type in a
Spanish sample [105]. A confirmatory study revealed
association with investigated eating disorder subtypes
(restricting AN, binge eating/purging AN) in a case–con-
trol study of 1,142 Caucasian patients with EDs consecu-
tively recruited in six different centers from five European
countries (France, Germany, Italy, Spain and UK) [106].
This finding was replicated by some [39, 107], but not all
studies [84, 108, 109]. Beside BDNF, association studies of
its receptors neurotrophic tyrosine kinase receptor types 2
and 3 (NTRK2 and NTRK3) revealed an association to
eating disorders [110, 111]. These data point to the neu-
rotrophin family as key regulators of eating behavior and as
potential susceptibility factors for EDs.
Endocannabinoid system
One of the endogenous systems that, due to its therapeutic
potential in the treatment of obesity [112], recently reached
scientific interest for ED is the endocannabinoid system.
Both exogenous and endogenous cannabinoids stimulate
food intake through activation of the cannabinoid receptor
1 (CNR1). The central CNR1 as well as the major endo-
cannabinoid degrading enzymes fatty acid amide hydrolase
(FAAH), N-acylethanolamine-hydrolyzing acid amidase
(NAAA) and monoglyceride lipase (MGLL) are implicated
in mediating the orexigenic effects of cannabinoids. Ini-
tially, Siegfried et al. [43] investigated an (AAT)n repeat in
the downstream flanking region of CNR1 and found that
the 14-repeat allele was preferentially transmitted in the
binge eating/purging AN group but not in the restricting
AN group. The 13-repeat allele was slightly more often
transmitted in the restricting AN group. As the sample
comprised only 52 families, this finding should be viewed
with caution in light of the small sample size. A second
study on the endocannabinoid system in patients with AN
pertained to the previously described (AAT)n repeat as
well as a total of 15 SNPs in CNR1, FAAH, NAAA or
MGLL in up to 91 German AN trios. Evidence for asso-
ciation (measured by transmission disequilibrium test) of
any of the SNPs or the (AAT)n repeat in AN was not
detected [113].
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Genes with effect on BMI from genome-wide
association studies
The neuroendocrine and molecular genetic pathways
involved in body weight regulation might also be of major
importance for eating disorders as suggested by identified
common molecular mechanisms for, e.g., BN and obesity
[29, 114, 115]. The first GWAS for BMI and obesity
marked the beginning of a new hypothesis-free era to
unravel the neurobiological mechanisms involved in body
weight regulation e.g., [116–118]. Consequently, a recent
report focussed on GWAS-based candidate gene variants
[119] to test for association with AN and to investigate a
combined effect of BMI-increasing alleles (as derived from
the original GWA studies) on the risk of developing AN.
However, association between individual SNPs and AN
was not detected; combined effects of BMI-increasing
alleles were also not found.
Genome-wide linkage studies
Despite considerable efforts hardly any of the candidate
gene analyses (exceptions: 5HT2A receptor; BDNF; see
Table 2) has yielded unequivocal and clearly confirmed
evidence for the involvement of specific alleles in the eti-
ology of eating disorders. The candidate gene approach in
eating disorders is hampered by the fact that there is no
clear-cut evidence implicating a specific regulatory system.
In this situation a systematic genome-wide approach that
does not rely on any a priori hypotheses as to the under-
lying genes offers a useful alternative to detect genes
involved in the etiology of eating disorders.
Anorexia nervosa
For AN, an international, multi-site collaborative group
(The Price Foundation Collaborative Group) [120] col-
lected a large study group of 196 AN patients and 237
affected relatives [AN, BN or eating disorders not other-
wise specified (EDNOS)]. The genome-wide linkage study
[121] using 386 microsatellite markers, revealed a single
non-significant multipoint nonparametric linkage score
(NPL) above 1.5 on chromosome 4. NPL[1 were observed
at additional markers on chromosome 4, 11, 13 and 15
[121]. Linkage analysis in a subset (n = 37) of families of
individuals with restricting AN, the highest multipoint NPL
score observed was 3.03, at marker D1S3721 on chromo-
some 1p. Using the same data set, an additional multipoint
affected sibling pair (ASP) linkage analysis was performed
specifically devised to incorporate covariates. By exploring
seven attributes thought to typify individuals with eating
disorders, two variables (drive-for-thinness and obsessio-
nality) were identified, which delimit populations among
the ASPs. For both of these traits, or covariates, there were
clusters of ASPs who were highly concordant for these
Table 2 Linkage studies for eating disorders
Chr Grice et al. [121]
AN sample
Devlin et al. [122]
AN sample
Bulik et al. [126]
BN sample
Bacanu et al. [125]
AN and BN samples
Position
in cM
Mulitipoint
NPL
(AN sample)
Mulitipoint NPL
(subsample
with ANR)
Position
in cM
LOD score
(covariate
obsessionality
in AN)
Position
in cM
MLS
(BN
sample)
Position
in cM
LOD
(AN
sample)
Position
in cM
LOD
(BN
sample)
1 NR NR NR 202 1.06 NR NR 206 1.549 208 0.773
2 186 0.12 1.70 184 1.12 NR NR 134 0.73 NR NR
4 25 1.42 1.82 22 1.10 NR NR NR NR NR NR
6 NR NR NR NR NR NR NR 153 1.052 179 0.944
10 NR NR NR NR NR 24 2.70 NR NR NR NR
10 NR NR NR NR NR 44 2.92 NR NR NR NR
11 NR NR NR NR NR NR NR 136 0.406 100 1.039
13 NR NR NR 29 1.18 NR NR 15 0.525 NR NR
16 22 0.78 1.70 NR NR NR NR NR 15 0.88
Results were included if at least one signal with a LOD[2 was detected or an initial signal was confirmed or narrowed down in the subanalyses
for the same phenotype. Please note that the results of Grice et al. [121], Devlin et al. [122], and Bacanu et al. [125] are based on the same data
set of families ascertained via a patient with AN or BN
AN anorexia nervosa, ANR anorexia nervosa restricting type, BN bulimia nervosa, cM centi Morgan, NPL nonparametric linkage score, MLS
multipoint maximum LOD scores, NR not reported
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traits. When these covariates were incorporated into the
ASP linkage analysis, both jointly and separately, several
regions of suggestive linkage were found: one close to
genome-wide significance on chromosome 1, chromosome
2 and on chromosome 13. By comparing these results with
those implemented using more standard linkage methods,
covariates that convey substantial information for the
linkage analysis were found [122].
Initial candidate gene analyses pertaining to the linkage
region on chromosome 1p36.3–34.3 described above have
been published [123, 124]. Linkage analysis of polymor-
phisms in the serotonin 1D receptor gene (5-HT1DR) and
the opioid delta receptor gene (OPRD1) together with 33
microsatellite markers in families including relative pairs
concordantly affected with restricting AN (N = 37) sub-
stantially increased the evidence for linkage of this region
to restricting AN. Statistically significant genotypic, allelic,
and haplotypic association to AN was observed at 5-
HT1DR and OPRD1 [123]. Brown et al. [124] conducted
an independent association study to replicate this finding.
One of 4 genotyped SNPs in 5-HTR1D supported the
hypothesis that the 5-HTR1D gene is involved in suscep-
tibility to AN, whereas in OPRD1 3 out of 6 investigated
SNPs were found to be nominally associated to AN [124].
However, further analyses are required to validate these
findings. Currently, there is no evidence to suggest that any
of the polymorphisms examined has a functional conse-
quence on the biological activity of 5-HT1DR and OPRD1
[124].
The same genome scan for AN was subsequently used to
increase the likelihood of finding genetic variation con-
ferring liability to eating disorders. Bacanu et al. [125]
measured over 100 attributes thought to be related to lia-
bility to eating disorders in affected individuals from
multiplex families of two cohorts: one recruited through a
proband with AN (AN cohort); the other recruited through
a proband with BN (BN cohort, see below). By a multilayer
decision process based on expert evaluation and statistical
analysis, six traits were selected for linkage analysis: ob-
sessionality (OBS), age at menarche (MENAR) and anxi-
ety (ANX) for quantitative trait locus (QTL) linkage
analysis, and lifetime minimum BMI, concern over mis-
takes (CM) and food-related obsessions (OBF) for covari-
ate-based linkage analysis. Results from the AN cohort
were less compelling than those for BN (see below): The
investigators detected two suggestive signals (OBS, ANX)
for QTL linkage analysis and five suggestive signals (BMI,
CM, OBF) for covariate-based linkage analysis. Despite
multiple analyses, correction for multiple testing was not
performed. Hence, it remains elusive if these peak regions
indeed harbor gene variants underlying the genetic sus-
ceptibility to AN. Fine mapping or a confirmed positional
candidate gene study have not been published yet.
Bulimia nervosa
A linkage analysis on 308 multiplex families with eating
disorders that were identified through a proband with BN
yielded a double peak, with the highest nonparametric
multipoint maximum LOD score (MLS) on chromosome
10 [126]. Linkage analysis was performed in a subset of
133 families in which at least two affected relatives
reported a symptom pattern that included self-induced
vomiting. The highest linkage peak provided evidence for
the presence of a susceptibility locus for BN on chromo-
some 10p [126]. Interestingly, this region already showed
up in full and partial genome scans for obesity [54, 88, 127,
128]; attempts to identify the underlying gene variant(s)
have however not led to clear-cut results [129, 130].
Nevertheless, a gene on chromosome 10p might well be
involved in both obesity and BN. Another region on 14q
met the criterion for genome-wide suggestive linkage for
BN at 62 cM from p-ter [126]. The underlying genes for
BN have not been described yet.
As described above, Bacanu et al. [125] determined over
100 attributes thought to be related to liability to eating
disorders. The BN cohort produced the largest linkage
signals, a QTL linkage analysis revealed four suggestive
signals for MENAR and ANX; covariate-based linkage
analyses revealed both significant and suggestive linkages
for BMI, CM and OBF. Overlap between the two cohorts
was minimal for substantial linkage signals. To our
knowledge, candidate gene analyses for the chromosomal
regions identified for BN have not been published yet.
Genome-wide association studies (GWAS)
Within the last 3 years the number of genetic association
studies using large numbers of genetic markers (up to
1,000,000) to search for genetic variation underlying
common diseases like obesity, diabetes, cardiovascular
disease and cancer has increased dramatically. GWAS rely
on the assumption that linkage disequilibrium (LD) enables
one SNP to act as a surrogate marker for association to
other sequence variants in the same region [131]. By
genotyping a large number of SNPs, there is a good chance
that at least one SNP will be in LD with common func-
tional variant(s) relevant for the investigated phenotype.
Genome-wide association studies represent a major step
forward in the study of common genetic variation in
complex diseases like eating disorders. Until today, several
GWAS revealed previously unknown gene-disease asso-
ciations, e.g., FTO and obesity [116, 117]. There are cur-
rently no published GWAS for eating disorders. To our
knowledge, the first GWAS for AN will be conducted in
the nearest future. One study is for instance funded by the
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Wellcome Trust and will soon be conducted by the Inter-
national Wellcome Trust Case Control Consortium
(WTCCC3) on 4,000 patients with AN and population-
based controls.
Epigenetics
Epigenetic factors are thought to mediate, at least in part,
the relationship between the genome and the environment.
Research on epigenetic factors underlying eating disorders
is at the very beginning. A first study revealed global DNA
hypomethylation, but at the same time DNA hypermethy-
lation of the alpha synuclein gene promoter in females with
AN [132]. Two further studies investigated whether the
mRNA expression of dopaminergic genes or of genes for
the peptide hormones vasopressin and atrial natriuretic
peptide (ANP) are altered in blood of patients suffering
from eating disorders. It was also analyzed if these alter-
ations can be explained by changes in the promoter specific
DNA methylation of these genes [67, 133]. The primary
results in a very small sample (n = 46) pointed to a dis-
turbed expression of the dopaminergic genes and ANP.
Further studies in independent samples are necessary to
provide more insight into the epigenetic dysregulation of,
e.g., dopaminergic neurotransmission in the pathophysiol-
ogy of eating disorders.
Eating disorders sub(pheno)types and endophenotypes
The definition of ED sub(pheno)types and endophenotypes
and their use for genetic association studies to reduce the
heterogeneity in samples based on a clinical diagnostic
category has been widely discussed, e.g., [9, 134].
Regarding sub(pheno)types we refer to the findings of
Ribases et al. [104, 105, 114] already mentioned above.
First studies showed that the 66Met variant of the BDNF
Val66Met polymorphism was associated only with the
restricting type of AN, whereas it was not associated with
AN in general. Hence, a mere analysis of the gene in AN
cases versus controls, at the given sample size, would have
led to the wrong assumption that the gene is not involved in
AN.
Bulik et al. [9] defined endophenotypes as measurable
neurophysiological, biochemical, endocrinological, neuro-
anatomical, cognitive, or neuropsychological components
see also [135]. Additionally, they are heritable, cosegregate
with a psychiatric clinical phenotype in the general popu-
lation, are state independent, and are found in non-affected
family members at a higher rate than in the general pop-
ulation [135–137]. Examples of candidate endophenotypes
are impaired set-shifting [138], excessive exercise [139],
weak coherence [140] or endophenotypes related to tem-
perament like thin-ideal internalization, ineffectiveness,
body dissatisfaction and sensitivity to punishment [141].
Specific susceptibility gene variants may underly endo-
phenotypes, which in turn may predispose individuals to
develop eating disorders and related conditions. To date
standardized definitions for endophenotypes of eating dis-
orders are still missing. As a consequence, results of
studies investigating endophenotypes and genetic variants
are hard to compare. Thus, their impact may become
clearer once studies circumventing methodological flaws
like small sample sizes, biases in sample ascertainment
(e.g., population stratification) or the testing of multiple
subsamples and subphenotypes without addressing the
multiple testing issues are performed [142].
Gene 3 environment interactions
Both genetic and environmental factors contribute to the
development of complex diseases like eating disorders. If
a genetic factor requires the presence of an environ-
mental factor (or vice versa) to result in increased risk, a
situation of gene 9 environment (G 9 E) interactions is
given. Interacting genetic and environmental factors are
distinguished by small to moderate effects. A number of
genetic variants might affect several genes influencing
vulnerability to eating disorders. As an example, an
individual with genetic vulnerability to AN might
become ill by exposure to high-risk environments like
figure skating or fashion shows. While both the current
knowledge on genetic risk factors and on environmental
risk factors has been excellently reviewed previously
[143] the knowledge on G 9 E is limited. To our
knowledge, no studies have yet reported distinct findings
on G 9 E interactions in eating disorders. In part this
may be due to design challenges of G 9 E studies
reviewed in [144, 145]. Following Dempfle et al. [144],
the investigation of G 9 E interactions may be more
rewarding for the detailed characterization of identified
disease genes (i.e., at advanced stages of genetic
research) as strong G 9 E interactions may have also
contributed to the detection of the gene itself. To date,
variations in the 5-HT2A receptor gene as well as in the
BDNF gene represent the most consistently supported
genetic findings for eating disorders. As their genetic
impact on the etiology of ED was solidly shown, they are
presumably the best candidates to investigate interactions
with environmental factors. In the future, this list will
likely expand once the first large scale GWAS for eating
disorders are conducted. Ideally, genetic research will
help to improve the understanding of environmental risk
factors for eating disorders [15, 143].
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Conclusions and research directions
Similar to other complex disorders, genome-wide linkage
studies for eating disorder have not led to unequivocally
confirmed genes involved in these disorders. The same
holds true for the candidate gene studies summarized above,
which were often based on samples of small to moderate
size. Variations in the 5-HT2A receptor gene as well as the
Val66Met variant in BDNF might represent the first
exceptions from this rule. Inadequate power to detect
associations with small effect sizes and multiple post hoc
comparisons are the most common and obvious reasons for
contradictory findings. One has to bear in mind that eating
disorders likely have a polygenic etiology, each gene hav-
ing a relatively small effect. To address this issue, large-
scaled meta-analyses or studies of sufficient sample size and
more stringent significance levels [146] are needed. Recent
success of genetic research into other psychiatric disorders
[147] has demonstrated that large sample sizes encom-
passing several thousands of cases and controls are required
to identify and validate molecular genetic findings.
Studies which focus on subphenotypes (e.g., restricting
type of AN) may lead to more specific results see [104, 105,
114]. These findings will also require additional independent
confirmations, but still they also show the value of carefully
selected study groups and equally carefully derived candi-
date genes. The analyses of GWAS data will benefit from the
candidate genes analyses performed so far. Although these
analyses were mainly equivocal the list of analyzed genes
for eating disorders can and will be used for the GWAS.
These genes will be specifically and thoroughly analyzed in
a complementary hypothesis-driven approach. Regarding
body weight regulation, we might soon gain a deeper insight
into the molecular mechanisms due to the success of large-
scaled GWAS, e.g., [(Hinney et al., this issue), 118, 148].
Furthermore, it can also be expected that some of the gene
variants predisposing to obesity will play a role in the
genetic susceptibility to eating disorders [29, 119].
In sum, GWAS have been a very successful tool for the
identification of genes involved in various complex disorders
and phenotypes, e.g., reviewed in [149]. The first GWAS for
eating disorders are in progress and the results are eagerly
awaited. Meanwhile, it is of crucial importance to recruit
further patients with eating disorders in order to be in a solid
position to confirm potential GWAS signals. In particular
genes identified by epigenetic studies as well as studies
focusing on well-defined endophenotypes will become more
important to elucidate the etiology of eating disorders and to
ultimately develop new treatment strategies.
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